Murray Nevin, Turrisi Andrew T
University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
J Thorac Oncol. 2006 Mar;1(3):270-8. doi: 10.1016/s1556-0864(15)31579-3.
Although small-cell lung cancer (SCLC) makes up a smaller proportion of all lung cancers than it did 25 years ago, it remains a common cause of cancer mortality that requires more clinical and basic research than is currently underway. Trials of newer chemotherapy variations have failed to produce a regimen that is clearly superior to the two-drug combination of etoposide and cisplatin, which remains the standard of care for both limited and extensive stage SCLC. Paradoxically, advances in this systemic disease have come from radiotherapy innovations for limited SCLC, including addition of thoracic irradiation to systemic chemotherapy, more intense thoracic irradiation, early integration of thoracic irradiation with systemic chemotherapy, and prophylactic cranial irradiation.
尽管与25年前相比，小细胞肺癌（SCLC）在所有肺癌中所占比例较小，但它仍是癌症死亡的常见原因，需要比目前正在进行的更多的临床和基础研究。新型化疗方案的试验未能产生一种明显优于依托泊苷和顺铂两药联合方案的疗法，该联合方案仍是局限期和广泛期SCLC的标准治疗方案。矛盾的是，这种全身性疾病的进展来自局限期SCLC的放疗创新，包括在全身化疗中增加胸部照射、更强化的胸部照射、胸部照射与全身化疗的早期联合以及预防性脑照射。
